Quick Answer
Syndax Pharmaceuticals Inc reported Total Assets of $529.71 million for the year ending 2025.
- Syndax Pharmaceuticals Inc showed a decrease of -26.9% in Total Assets from 2024 to 2025.
- This data is from Syndax Pharmaceuticals Inc's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: $136.26 million | Q2 2016: $127.86 million | Q3 2016: $117.73 million | Q1 2017: $97.67 million | Q2 2017: $134.67 million | Q3 2017: $124.49 million | Q1 2018: $119.96 million | Q2 2018: $105.37 million | Q3 2018: $96.47 million | Q1 2019: $99.39 million | Q2 2019: $87.39 million | Q3 2019: $76.38 million | Q1 2020: $105.16 million | Q2 2020: $192.63 million | Q3 2020: $179.31 million | Q1 2021: $279.67 million | Q2 2021: $263.06 million | Q3 2021: $239.50 million | Q1 2022: $422.22 million | Q2 2022: $406.44 million | Q3 2022: $359.69 million | Q1 2023: $459.83 million | Q2 2023: $431.34 million | Q3 2023: $399.22 million | Q1 2024: $543.03 million | Q2 2024: $476.95 million | Q3 2024: $425.81 million | Q1 2025: $640.71 million | Q2 2025: $596.15 million | Q3 2025: $551.79 million.
- Over the full 11 years of available data (2015 to 2025), Syndax Pharmaceuticals Inc's Total Assets has grown by 489.2%.
- Historical annual values: Fiscal year 2025: $529.71 million | Fiscal year 2024: $724.82 million | Fiscal year 2023: $612.88 million | Fiscal year 2022: $497.24 million | Fiscal year 2021: $449.66 million | Fiscal year 2020: $300.61 million | Fiscal year 2019: $63.53 million | Fiscal year 2018: $83.94 million | Fiscal year 2017: $137.19 million | Fiscal year 2016: $109.01 million | Fiscal year 2015: $89.90 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: